CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

The Department of Health and Human Services plans to cancel contracts and pull funding for some vaccines being developed to ...

Kennedy said in a statement that he wants the health department to move away from mRNA vaccines, calling on the department to ...

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

While the drugmaker reaffirmed its 2025 revenue guidance of $61bn to $64bn, it raised its full-year 2025 profit outlook. Pfizer now expects to earn $2.90 to $3.10 per share, compared with its previous ...

The U.S. Department of Health and Human Services said on Tuesday it would wind down mRNA vaccine development activities under ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

The company posted strong second-quarter results and reaffirmed its guidance for 2025. Enbridge posted EBITDA of C$4.6 ...